Contrasting Genelux (GNLX) & The Competition

Genelux (NASDAQ:GNLX) is one of 846 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Genelux to similar businesses based on the strength of its analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.

Profitability

This table compares Genelux and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
Genelux Competitors	-12,283.59%	-195.39%	-30.85%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Genelux and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1	0	2	1	2.75
Genelux Competitors	9904	15278	45630	1595	2.54

Genelux currently has a consensus target price of $20.00, suggesting a potential upside of 963.83%. As a group, “Biotechnology” companies have a potential upside of 120.28%. Given Genelux’s stronger consensus rating and higher probable upside, research analysts clearly believe Genelux is more favorable than its rivals.

Institutional & Insider Ownership

37.3% of Genelux shares are held by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Genelux and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Genelux	$10,000.00	-$32.15 million	-2.19
Genelux Competitors	$704.22 million	$10.96 million	-15.00

Genelux’s rivals have higher revenue and earnings than Genelux. Genelux is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Genelux has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Genelux’s rivals have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.

Summary

Genelux rivals beat Genelux on 8 of the 13 factors compared.

About Genelux

Genelux Corporation is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. The company’s lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, genetically modified oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating an immune response against cancer. Genelux is evaluating Olvi-Vec in combination with other treatments across multiple solid-tumor indications. Its clinical development efforts have included ovarian cancer, where the candidate is being studied in patients with advanced or recurrent disease, as well as other potential applications in cancers such as colorectal and lung cancer.